30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

ConforMIS Reports 1Q19 Revenue of $20.6MM, +5% vs. 1Q18 -


ConforMIS posts 1Q19 revenue of USD $20.6MM, +5% vs. 1Q18.

  • U.S. revenue increased almost 10% driven by sales of iTotal PS
  • iTotal PS sales grew 30% year over year
  • iTotal PS now accounts for 37% of all product revenue, up from 30% last year
  • Ex-U.S. sales continued to decline, especially in Germany
  • Company faced operational issues with final stages of CAD outsourcing
  • ConforMIS funded a study published in Clinical Orthopaedics and Related Research that examined the knee anatomy of 24,000 patients and showed a high degree of variability, supporting the use of customized knee implants


ConforMIS’ segment sales and growth on an as-reported basis are as follows ($MM).

  1Q19 1Q18 $ Chg % Chg
Joint Replacement Knees $20.1 $19.7 $0.5 2.5%
Joint Replacement Hips * $0.5      
Total $20.6 $19.7 $1.0 5.0%

* Limited launch 3Q18, full launch 2H19

ConforMIS’ product revenue by geographic region is as follows ($MM).

Geographic Region 1Q19 1Q18 $ Chg % Chg
US $17.6 $16.0 $1.5 9.5%
Ex-US $2.9 $3.5 -$0.5 -15.7%
Total $20.5 $19.5 $1.0 5.1%

Net earnings are as follows.

1Q19 Amount ($MM) % of Sales
Sales $20.6  
   Cost of Sales -$10.8 52.4%
   Sales and Marketing -$8.2 39.6%
   R & D -$2.9 14.1%
   General and Admin -$5.3 25.8%
   Other -$1.0 4.8%
Net Earnings -$7.6 -36.8%


Source: ConforMIS

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.